NCI Community Oncology Research Program - Kansas City (NCORP-KC)
NCI Community Oncology Research Program - Kansas City (NCORP-KC)




NCI Community Oncology Research Program - Protocol Summary

SWOG S1400F - "A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients with Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (LUNG-MAP NON-MATCH SUB-STUDY)"

The summary below serves as a brief review of the treatment plan and eligibility for the protocol.


This summary is not intended to be used in place of the full eligibility & treatment information in the protocol.
 

Please contact NCORP-KC for complete protocol information.



Print This Summary

Lung Clinical Trial

CANCER TYPE: Non-Small Cell - Stage IV
RESEARCH BASE: SWOG
NCT NUMBER: NCT03373760
HIPPA FORM: DOWNLOAD HIPPA FORM

Consent Form: VIEW CONSENT FORM
UPDATED ON 08/17/2018 (16:13:55)

BRIEF DESCRIPTION

Stage IV or recurrent, PDL-1 positive, Durvalumab and Tremelimumab.  DCP-001 Eligible



NOTES


Treatment

Tremelimumab 75 mg, IV, over 60 minutes, Day 1, up to 4 cycles

Durvalumab 1500 mg IV, over 60 minutes, Day 1, until progression

Cycle = 28 days



ELIGIBILITY

  • Patients must have been assigned to S1400F.
  • Patients must have progressed during or after prior platinum-based chemotherapy. For patients whose only prior platinum-based chemotherapy regimen was for Stage I-III disease (i.e. patient has not received any platinum-based chemotherapy for Stage IV or recurrent disease), disease progression on platinum-based chemotherapy must have occurred within one year from the last date that patient received that therapy. Patients must also have experienced disease progression during or after anti-PD1 or anti-PD-L1 antibody monotherapy as their most recent line of treatment. Prior PD-1/PD-L1 combination therapy is not permitted [This criterion replaces common eligibility criteria in Section 5.3b.]
  • Prior exposure to CTLA-4 inhibitors (ipilimumab and tremelimumab) is not permitted. Prior exposure to the following is allowed: attenuated vaccines, antiEGFR agents, and GM- CSF.
  • Patients must not have received nitrosoureas or mitomycin-c within 42 days prior to sub-study registration.
  • Patients must not have any prior documented autoimmune or inflammatory disease (including inflammatory bowel disease, diverticulitis with the exception of diverticulosis, celiac disease, irritable bowel disease; Wegner syndrome; Hashimoto syndrome) within 3 years prior to sub-study registration. Patients with vitiligo, immune-mediated alopecia, Grave’s disease, or psoriasis requiring systemic treatment within the past 2 years are not eligible. Patients with hypothyroidism (e.g. post Hashimoto syndrome) who are stable on hormone replacement therapy are eligible.
  • Patients must not have any history of primary immunodeficiency.
  • Patients must not have received any immunosuppressive medication within 28 days prior to sub-study registration and must not be planning to receive these medications while on protocol therapy. Systemic corticosteroids must be stopped at least 24 hours prior to sub-study registration. However, intranasal and inhaled corticosteroids are allowed at any time before and during protocol therapy
  • Patients must not have experienced a Grade 3 or worse immune-related adverse event (irAE) (except asymptomatic nonbullous/nonexfoliative rash) or any unresolved irAE Grade 2, nor have experienced a toxicity that led to permanent discontinuation of prior anti-PD-1/PD-L1 immunotherapy.
  • Patients must not have any history of organ transplant that requires use of immunosuppressives.
  • Patients must not have any known allergy or reaction to any component of the MEDI4736 (Durvalumab) and/or tremelimumab formulation.
  • Patients must not have clinical signs or symptoms of active tuberculosis infection.
  • Patients must not have received a live attenuated vaccination within 28 days prior to sub-study registration.
  • Patients must not have known HIV, or a known positive test for Hepatitis B virus surface antigen (HBV sAg), or Hepatitis C virus ribonucleic acid (HCV antibody) indicating current acute or chronic infection. Patients with a positive hepatitis C antibody with a negative viral load are allowed. [This criterion replaces common eligibility criteria in Section 5.3n and 5.3m.]
  • Patients must have a TSH with reflex Free T3/Free T4 (if TSH is out of normal range) and EKG obtained within 7 days prior to sub-study registration. Additional timepoints are noted in Section 9.0, Study Calendar.
  • Patients must also be offered participation in banking and in the correlative studies for collection and future use of specimens as described in S1400F Section 15.0
  • .Patients whose biomarker profiling results indicate the presence of an EGFR mutation or EML4/ALK fusion are not eligible. Due to existence of approved therapies
  • Patients must not have received any prior systemic therapy (systemic chemotherapy, immunotherapy or investigational drug) within 21 days prior to substudy registration. Patients must have recovered (≤ Grade 1) from any side effects of prior therapy. Patients must not have received any radiation therapy within 14 days prior to sub-study registration. (See Section 5.3e for criteria regarding therapy for CNS metastases).
  • Patients must have measurable disease (see S1400 Section 10.1) documented by CT or MRI. The CT from a combined PET/CT may be used to document only nonmeasurable disease unless it is of diagnostic quality as defined in S1400 Section 10.1c. Measurable disease must be assessed within 28 days prior to sub-study registration. Pleural effusions, ascites and laboratory parameters are not acceptable as the only evidence of disease. Non-measurable disease must be assessed within 42 days prior to sub-study registration. All disease must be assessed and documented on the Baseline Tumor Assessment Form. Patients whose only measurable disease is within a previous radiation therapy port must demonstrate clearly progressive disease (in the opinion of the treating investigator) prior to registration. See S1400F Sections 15.0 and S1400 Section 18.1c for guidelines and submission instructions for required central radiology review.
  • Patients must have a CT or MRI scan of the brain to evaluate for CNS disease within 42 days prior to sub-study registration. Patient must not have leptomeningeal disease, spinal cord compression or brain metastases unless: (1) metastases have been locally treated and have remained clinically controlled and asymptomatic for at least 14 days following treatment, and prior to registration, AND (2) patient has no residual neurological dysfunction and has been off corticosteroids for at least 24 hours prior to sub-study registration.
  • Patient must have fully recovered from the effects of surgery at least 14 days prior to sub-study registration.
  • Patients must not be planning to receive any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment. Concurrent use of hormones for non-cancer-related conditions (e.g., insulin for diabetes and hormone replacement therapy) is acceptable.
  • Patients must have an ANC ≥ 1,500/mcl, platelet count ≥ 100,000 mcl, and hemoglobin ≥ 9 g/dL obtained within 28 days prior to sub-study registration. Patients must have adequate hepatic function as defined by serum bilirubin ≤ Institutional Upper Limit of Normal (IULN) and either ALT or AST ≤ 2 x IULN within 28 days prior to sub-study registration (if both ALT and AST are done, both must be < 2 IULN). For patients with liver metastases, bilirubin and either ALT or AST must be ≤ 5 x IULN (if both ALT and AST are done, both must be ≤ 5 x IULN).
  • Patients must have a serum creatinine ≤ the IULN OR measured or calculated creatinine clearance ≥ 50 mL/min using the following Cockroft-Gault Formula
  • Patients must have Zubrod performance status 0-1 (see S1400 Section 10.4) documented within 28 days prior to sub-study registration.
  • Patients must not have any Grade III/IV cardiac disease as defined by the New York Heart Association Criteria (i.e., patients with cardiac disease resulting in marked limitation of physical activity or resulting in inability to carry on any physical activity without discomfort), unstable angina pectoris, and myocardial infarction within 6 months, or serious uncontrolled cardiac arrhythmia (see S1400 Section 18.1b).
  • Prestudy history and physical exam must be obtained within 28 days prior to substudy registration.
  • No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for five years.
  • Patients must not be pregnant or nursing.
  •  





  © 2013-2018 All Rights Reserved. Privacy Policy | Terms & Conditions
NCI Community Oncology Research Program - Kansas City (NCORP-KC)
Questions? Call: +1-913-948-5588 | Contact Us
4121 W. 83rd St., Suite 259 Prairie Village, KS 66208 USA